Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: An 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients

      This paper is only available as a PDF. To read, Please Download here.


      Background:S-adenosylmethionine (SAMe) has antiinflammatory and analgesie effects and has been reported to ameliorate the pain and dysfunction of osteoarthritis (OA). The metabolism of SAMe can be affected by geographic or ethnic factors. However, its efficacy and tolerability versus NSAIDs have not been reported in an Asian population.
      Objective: This study compared the efficacy and tolerability of SAMe 1200 mg/d and nabumetone 1000 mg/d in Korean patients with knee OA.
      Methods: This study was an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV clinical trial. Eligible patients were aged >18 years and had knee OA according to the clinical and radiologic criteria of the American College of Rheumatology, with a symptom duration of ≥3 months and with a baseline pain rating of >40 mm on a visual analog scale (VAS) or a pain rating on the VAS that was increased by >10 mm or 20% during the washout period compared with the screening visit. After a washout period of 2 weeks, patients with OA were randomly assigned to receive SAMe 1200 mg/d (400 mg TID) or nabumetone 1000 mg once a day in the evening for 8 weeks. The primary end point was the patient's assessment of pain intensity using a VAS at week 8, and the secondary end points were functional class, patient's global assessment of disease status, physician's global assessment of response to therapy, and the Western Ontario and McMaster Universities (WOMAC) index. Adverse events were assessed based on spontaneous reports by patients during interviews and by laboratory tests.
      Results: One hundred thirty-four patients, all Asians, were randomly allocated to 1 of 2 treatment groups: 67 patients (56 women, 11 men; mean [SD] age, 63.9 [8.2] years) received SAMe 400 mg TID, and 67 patients (60 women, 7 men; mean age, 62.1 [8.4] years) received nabumetone 1000 mg once daily for 8 weeks. An analysis of changes in pain intensity between weeks 0 and 8 found that both SAMe and nabumetone effectively reduced pain intensity from baseline in each group (mean [SD] change: SAMe, −13.0 [20.8] mm, P < 0.001; nabumetone, −15.7 [20.9] mm, P < 0.001), and the degree of decrease in pain intensity was not significantly different between groups. Secondary end points showed significant improvements from baseline to 8 weeks in both groups. The patient's global assessment of disease status, physician's global assessment of response to therapy, and WOMAC index scores were not significantly different between the groups. Use of acetaminophen as rescue medication did not differ significantly between the groups during weeks 0 to 4 (SAMe, 88.5% [54/61]; nabumetone, 81.3% [52/64]) or weeks 4 to 8 (SAMe, 79.5% [35/44]; nabumetone, 68.5% [37/54]). No significant differences were observed between the treatments in the proportions of patients with all adverse events (SAMe, 35.8% [24/67]; nabumetone, 31.3% [21/67]), drugrelated clinical or laboratory-determined adverse events (SAMe, 22.4% [15/67]; nabumetone, 25.4% [17/67]), or discontinuations due to any adverse events (SAMe, 13.4% [9/67]; nabumetone, 10.4% [7/67]).
      Conclusion: This study found no significant differences in pain relief or tolerability between treatment with SAMe or nabumetone over 8 weeks in Korean patients with knee OA.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Oliveria SA
        • Felson DT
        • Reed JI
        • et al.
        Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization.
        Arthritis Rheum. 1995; 38: 1134-1141
        • American College of Rheumatology Subcommittee on Osteoarthritis Guidelines
        Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update.
        Arthritis Rheum. 2000; 43: 1905-1915
        • Jordan KM
        • Arden NK
        • Doherty M
        • et al.
        • Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT
        EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).
        Ann Rheum Dis. 2003; 62: 1145-1155
        • Wolfe MM
        • Lichtenstein DR
        • Singh G
        Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs [published correction appears in N Engl J Med. 1999;341:548].
        N Engl J Med. 1999; 340: 1888-1899
        • Hernández-Diaz S
        • Garcia-Rodríguez LA
        Epidemiologic assessment of the safety of conventional nonsteroidal antiinflammatory drugs.
        Am J Med. 2001; 110: 20S-27S
        • Farkouh ME
        • Greenberg BP
        An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
        Am J Cardiol. 2009; 103: 1227-1237
        • Gregory PJ
        • Sperry M
        • Wilson AF
        Dietary supplements for osteoarthritis.
        Am Fam Physician. 2008; 77: 177-184
        • Bottiglieri T
        S-Adenosyl-L-methionine (SAMe): From the bench to the bedside-molecular basis of a pleiotrophic molecule.
        Am J Clin Nutr. 2002; 76: 1151S-1157S
        • Harmand MF
        • Vilamitjana J
        • Maloche E
        • et al.
        Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study.
        Am J Med. 1987; 83: 48-54
        • Barceló HA
        • Wiemeyer JC
        • Sagasta CL
        • et al.
        Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits.
        Am J Med. 1987; 83: 55-59
        • Gutierrez S
        • Palacios I
        • Sánchez-Pernaute O
        • et al.
        SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells.
        Br J Rheumatol. 1997; 36: 27-31
        • Caruso I
        • Pietrogrande V
        Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
        Am J Med. 1987; 83: 66-71
        • Glorioso S
        • Todesco S
        • Mazzi A
        • et al.
        Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
        Int J Clin Pharmacol Res. 1985; 5: 39-49
        • Pellegrini P
        S-adenosylmethionine (SAMe) in osteoarthrosis; a double-blind crossover peroral study [in Italian].
        G Clin Med. 1980; 61: 616-627
        • Maccagno A
        • Di Giorgio EE
        • Caston OL
        • Sagasta CL
        Doubleblind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis.
        Am J Med. 1987; 83: 72-77
        • Vetter G
        Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis.
        Am J Med. 1987; 83: 78-80
        • Najm WI
        • Reinsch S
        • Hoehler F
        • et al.
        S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495].
        BMC Musculoskelet Disord. 2004; 5: 6
        • Bradley JD
        • Flusser D
        • Katz BP
        • et al.
        A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis.
        J Rheumatol. 1994; 21: 905-911
        • Loenen WA
        S-adenosylmethionine: Jack of all trades and master of everything?.
        Biochem Soc Trans. 2006; 34: 330-333
        • Chambers JC
        • Obeid OA
        • Refsum H
        • et al.
        Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men.
        Lancet. 2000; 355: 523-527
        • Wilcken B
        • Bamforth F
        • Li Z
        • et al.
        Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide [published correction appears in J Med Genet. 2004;41:400].
        J Med Genet. 2003; 40: 619-625
        • Huang JQ
        • Sridhar S
        • Hunt RH
        Gastrointestinal safety profile of nabumetone: A meta-analysis.
        Am J Med. 1999; 107 (discussion): 55S-61S
        • Huang JQ
        • Sridhar S
        • Hunt RH
        Gastrointestinal safety profile of nabumetone: A meta-analysis.
        Am J Med. 1999; 107: 61S-64S
        • Scott DL
        • Palmer RH
        Safety and efficacy of nabumetone in osteoarthritis: Emphasis on gastrointestinal safety.
        Aliment Pharmacol Ther. 2000; 14: 443-452
        • Arai Y
        • Tanaka K
        • Ushijima H
        • et al.
        Low direct cytotoxicity of nabumetone on gastric mucosal cells.
        Dig Dis Sci. 2005; 50: 1641-1646
        • Soeken KL
        • Lee WL
        • Bausell RB
        • et al.
        Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis.
        J Fam Pract. 2002; 51: 425-430
        • Witte S
        • Lasek R
        • Victor N
        Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis [in German].
        Orthopade. 2002; 31: 1058-1065
        • Altman R
        • Asch E
        • Bloch D
        • et al.
        • Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association
        Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee.
        Arthritis Rheum. 1986; 29: 1039-1049
        • Kellgren JH
        • Lawrence JS
        Radiological assessment of osteo-arthrosis.
        Ann Rheum Dis. 1957; 16: 494-502
        • von Schrader HW
        • Buscher G
        • Dierdorf D
        • et al.
        Nabumetone—a novel anti-inflammatory drug: Bioavailability after different dosage regimens.
        Int J Clin Pharmacol Ther Toxicol. 1984; 22: 672-676
        • Hochberg MC
        • Chang RW
        • Dwosh I
        • et al.
        The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis.
        Arthritis Rheum. 1992; 35: 498-502
        • Bellamy N
        WOMAC Osteoarthritis Index User Guide. Version VII. Brisbane, Australia2005
        • Lachin JM
        Introduction to sample size determination and power analysis for clinical trials.
        Control Clin Trials. 1981; 2: 93-113
        • di Padova C
        S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies.
        Am J Med. 1987; 83: 60-65
        • Cha HS
        • Koh JH
        • Jeon CH
        • et al.
        Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee.
        Int J Clin Pharmacol Ther. 2001; 39: 539-545